

# Christopher M Heaphy

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9223023/publications.pdf>

Version: 2024-02-01

97  
papers

5,267  
citations

126907

33  
h-index

91884

69  
g-index

106  
all docs

106  
docs citations

106  
times ranked

8341  
citing authors

#	ARTICLE	IF	CITATIONS
1	Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size. <i>Gut</i> , 2022, 71, 961-973.	12.1	60
2	Clinical implications of cell-of-origin epigenetic characteristics in non-functional pancreatic neuroendocrine tumors. <i>Journal of Pathology</i> , 2022, 256, 143-148.	4.5	9
3	Mutational Landscape and Outcomes of Conjunctival Melanoma in 101 Patients. <i>Ophthalmology</i> , 2022, 129, 679-693.	5.2	16
4	Novel forms of prostate cancer chemoresistance to successful androgen deprivation therapy demand new approaches: Rationale for targeting BET proteins. <i>Prostate</i> , 2022, 82, 1005-1015.	2.3	8
5	Investigating the Molecular and Phenotypic Differences in Pancreatic Neuroendocrine Tumor (PanNET) Cells with Functional Loss of Either <i>ATRX</i> or <i>DAXX</i> . <i>FASEB Journal</i> , 2022, 36, .	0.5	0
6	Therapeutic Vulnerability to ATR Inhibition in Concurrent NF1 and ATRX-Deficient/ALT-Positive High-Grade Solid Tumors. <i>Cancers</i> , 2022, 14, 3015.	3.7	10
7	The prostate tissue-based telomere biomarker as a prognostic tool for metastasis and death from prostate cancer after prostatectomy. <i>Journal of Pathology: Clinical Research</i> , 2022, 8, 481-491.	3.0	6
8	Differential mast cell phenotypes in benign versus cancer tissues and prostate cancer oncologic outcomes. <i>Journal of Pathology</i> , 2021, 253, 415-426.	4.5	13
9	SMARCA11 loss and alternative lengthening of telomeres (ALT) are enriched in giant cell glioblastoma. <i>Modern Pathology</i> , 2021, 34, 1810-1819.	5.5	8
10	Clinicopathological and molecular characterization of chromophobe hepatocellular carcinoma. <i>Liver International</i> , 2021, 41, 2499-2510.	3.9	6
11	Prognostic biomarkers in pancreatic neuroendocrine tumors. <i>Cancer Cytopathology</i> , 2021, 129, 841-843.	2.4	2
12	Oncogenic gene fusions in nonneoplastic precursors as evidence that bacterial infection can initiate prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	18
13	Obesity is Associated with Shorter Telomere Length in Prostate Stromal Cells in Men with Aggressive Prostate Cancer. <i>Cancer Prevention Research</i> , 2021, 14, 463-470.	1.5	3
14	Genetic Analysis of Small Well-differentiated Pancreatic Neuroendocrine Tumors Identifies Subgroups With Differing Risks of Liver Metastases. <i>Annals of Surgery</i> , 2020, 271, 566-573.	4.2	64
15	Assessment of ARX expression, a novel biomarker for metastatic risk in pancreatic neuroendocrine tumors, in endoscopic ultrasound fine-needle aspiration. <i>Diagnostic Cytopathology</i> , 2020, 48, 308-315.	1.0	20
16	Racial Difference in Prostate Cancer Cell Telomere Lengths in Men with Higher Grade Prostate Cancer: A Clue to the Racial Disparity in Prostate Cancer Outcomes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 676-680.	2.5	11
17	Pervasive promoter hypermethylation of silenced TERT alleles in human cancers. <i>Cellular Oncology (Dordrecht)</i> , 2020, 43, 847-861.	4.4	14
18	Telomere length alterations and ATRX/DAXX loss in pituitary adenomas. <i>Modern Pathology</i> , 2020, 33, 1475-1481.	5.5	13

#	ARTICLE	IF	CITATIONS
19	Alternative Lengthening of Telomeres and Differential Expression of Endocrine Transcription Factors Distinguish Metastatic and Non-metastatic Insulinomas. <i>Endocrine Pathology</i> , 2020, 31, 108-118.	9.0	32
20	Pancreatic acinar cell carcinomas and mixed acinar-neuroendocrine carcinomas are more clinically aggressive than grade 1 pancreatic neuroendocrine tumours. <i>Pathology</i> , 2020, 52, 336-347.	0.6	14
21	Generation and characterization of a cell line from an intraductal tubulopapillary neoplasm of the pancreas. <i>Laboratory Investigation</i> , 2020, 100, 1003-1013.	3.7	3
22	High Extratumoral Mast Cell Counts Are Associated with a Higher Risk of Adverse Prostate Cancer Outcomes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 668-675.	2.5	16
23	Telomere lengths differ significantly between small-cell neuroendocrine prostate carcinoma and adenocarcinoma of the prostate. <i>Human Pathology</i> , 2020, 101, 70-79.	2.0	5
24	HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: MEN1-related pancreatic NETs: identification of unmet clinical needs and future directives. <i>Endocrine-Related Cancer</i> , 2020, 27, T9-T25.	3.1	10
25	NFB-01. FUNCTIONAL CHARACTERIZATION OF ATRX LOSS IN NF1-ASSOCIATED GLIOMA AND MPNST. <i>Neuro-Oncology</i> , 2020, 22, iii417-iii418.	1.2	0
26	Molecular Pathology of High-Grade Prostatic Intraepithelial Neoplasia: Challenges and Opportunities. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2019, 9, a030403.	6.2	25
27	ATRX Mutations in Pineal Parenchymal Tumors of Intermediate Differentiation. <i>Journal of Neuropathology and Experimental Neurology</i> , 2019, 78, 703-708.	1.7	7
28	Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors. <i>Nature Medicine</i> , 2019, 25, 1260-1265.	30.7	120
29	Surviving Telomere Attrition with the MiDAS Touch. <i>Trends in Genetics</i> , 2019, 35, 783-785.	6.7	3
30	Functional Loss of <i>ATRX</i> and <i>TERC</i> Activates Alternative Lengthening of Telomeres (ALT) in LAPC4 Prostate Cancer Cells. <i>Molecular Cancer Research</i> , 2019, 17, 2480-2491.	3.4	25
31	Telomere alterations in neurofibromatosis type 1-associated solid tumors. <i>Acta Neuropathologica Communications</i> , 2019, 7, 139.	5.2	12
32	Cell division rates decrease with age, providing a potential explanation for the age-dependent deceleration in cancer incidence. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 20482-20488.	7.1	63
33	Mannose Receptor-positive Macrophage Infiltration Correlates with Prostate Cancer Onset and Metastatic Castration-resistant Disease. <i>European Urology Oncology</i> , 2019, 2, 429-436.	5.4	46
34	Analysis of Telomere Lengths in p53 Signatures and Incidental Serous Tubal Intraepithelial Carcinomas Without Concurrent Ovarian Cancer. <i>American Journal of Surgical Pathology</i> , 2019, 43, 1083-1091.	3.7	15
35	Alternative lengthening of telomeres, ATRX loss and H3K27M mutations in histologically defined pilocytic astrocytoma with anaplasia. <i>Brain Pathology</i> , 2019, 29, 126-140.	4.1	54
36	Adding the Team into T1 Translational Research: A Case Study of Multidisciplinary Team Science in the Evaluation of Biomarkers of Prostate Cancer Risk and Prognosis. <i>Clinical Chemistry</i> , 2019, 65, 189-198.	3.2	6

#	ARTICLE	IF	CITATIONS
37	A unique telomere DNA expansion phenotype in human retinal rod photoreceptors associated with aging and disease. <i>Brain Pathology</i> , 2019, 29, 45-52.	4.1	5
38	Cocaine use may induce telomere shortening in individuals with HIV infection. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 84, 11-17.	4.8	7
39	MYC drives overexpression of telomerase RNA ( <i>hTR</i> / <i>TERC</i> ) in prostate cancer. <i>Journal of Pathology</i> , 2018, 244, 11-24.	4.5	51
40	Current or recent smoking is associated with more variable telomere length in prostate stromal cells and prostate cancer cells. <i>Prostate</i> , 2018, 78, 233-238.	2.3	5
41	Genetic alterations associated with ALTERed telomeres. <i>Oncotarget</i> , 2018, 9, 33739-33740.	1.8	3
42	ATRX loss induces multiple hallmarks of the alternative lengthening of telomeres (ALT) phenotype in human glioma cell lines in a cell line-specific manner. <i>PLoS ONE</i> , 2018, 13, e0204159.	2.5	48
43	Subependymal giant cell astrocytoma-like astrocytoma: a neoplasm with a distinct phenotype and frequent neurofibromatosis type-1-association. <i>Modern Pathology</i> , 2018, 31, 1787-1800.	5.5	24
44	Racial differences in maternal and umbilical cord blood leukocyte telomere length and their correlations. <i>Cancer Causes and Control</i> , 2018, 29, 759-767.	1.8	3
45	Incidentally detected pancreatic neuroendocrine microadenoma with lymph node metastasis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 473, 649-653.	2.8	11
46	Alternative lengthening of telomeres and ATRX/DAXX loss can be reliably detected in FNAs of pancreatic neuroendocrine tumors. <i>Cancer Cytopathology</i> , 2017, 125, 544-551.	2.4	41
47	Absence of Cytomegalovirus in Glioblastoma and Other High-grade Gliomas by Real-time PCR, Immunohistochemistry, and <i>In Situ</i> Hybridization. <i>Clinical Cancer Research</i> , 2017, 23, 3150-3157.	7.0	52
48	Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival. <i>Clinical Cancer Research</i> , 2017, 23, 1598-1606.	7.0	101
49	Comprehensive assessment of <i>ATRX</i> mutation, protein expression, and alternative lengthening of telomeres (ALT) phenotype in grade II and III gliomas. <i>Journal of Clinical Oncology</i> , 2017, 35, 2064-2064.	1.6	2
50	Influence of In Utero Maternal and Neonate Factors on Cord Blood Leukocyte Telomere Length: Clues to the Racial Disparity in Prostate Cancer?. <i>Prostate Cancer</i> , 2016, 2016, 1-8.	0.6	11
51	High-resolution telomere fluorescence in situ hybridization reveals intriguing anomalies in germ cell tumors. <i>Human Pathology</i> , 2016, 54, 106-112.	2.0	8
52	Frequent alternative lengthening of telomeres and ATRX loss in adult NF1-associated diffuse and high-grade astrocytomas. <i>Acta Neuropathologica</i> , 2016, 132, 761-763.	7.7	23
53	Aberrant Menin expression is an early event in pancreatic neuroendocrine tumorigenesis. <i>Human Pathology</i> , 2016, 56, 93-100.	2.0	31
54	Inactivating ARID1A Tumor Suppressor Enhances TERT Transcription and Maintains Telomere Length in Cancer Cells. <i>Journal of Biological Chemistry</i> , 2016, 291, 9690-9699.	3.4	45

#	ARTICLE	IF	CITATIONS
55	Visualization of Telomere Integrity and Function In Vitro and In Vivo Using Immunofluorescence Techniques. <i>Current Protocols in Cytometry</i> , 2015, 73, 12.40.1-12.40.31.	3.7	37
56	Leukocyte telomere length and its association with mammographic density and proliferative diagnosis among women undergoing diagnostic image-guided breast biopsy. <i>BMC Cancer</i> , 2015, 15, 823.	2.6	3
57	Prostate stromal cell telomere shortening is associated with risk of prostate cancer in the placebo arm of the Prostate Cancer Prevention Trial. <i>Prostate</i> , 2015, 75, 1160-1166.	2.3	29
58	Prediagnostic Obesity and Physical Inactivity Are Associated with Shorter Telomere Length in Prostate Stromal Cells. <i>Cancer Prevention Research</i> , 2015, 8, 737-742.	1.5	11
59	Circulating leukocyte telomere length and risk of overall and aggressive prostate cancer. <i>British Journal of Cancer</i> , 2015, 112, 769-776.	6.4	73
60	Telomere length alterations unique to invasive lobular carcinoma. <i>Human Pathology</i> , 2015, 46, 1197-1203.	2.0	7
61	Functional isogenic modeling of BRCA1 alleles reveals distinct carrier phenotypes. <i>Oncotarget</i> , 2015, 6, 25240-25251.	1.8	9
62	Gastroenteropancreatic endocrine tumors. <i>Molecular and Cellular Endocrinology</i> , 2014, 386, 101-120.	3.2	32
63	Telomere length as a risk factor for hereditary prostate cancer. <i>Prostate</i> , 2014, 74, 359-364.	2.3	27
64	Alternative Lengthening of Telomeres Predicts Site of Origin in Neuroendocrine Tumor Liver Metastases. <i>Journal of the American College of Surgeons</i> , 2014, 218, 628-635.	0.5	34
65	Molecular and Morphologic Correlates of the Alternative Lengthening of Telomeres Phenotype in High-Grade Astrocytomas. <i>Brain Pathology</i> , 2013, 23, 237-243.	4.1	73
66	Chromophobe hepatocellular carcinoma with abrupt anaplasia: a proposal for a new subtype of hepatocellular carcinoma with unique morphological and molecular features. <i>Modern Pathology</i> , 2013, 26, 1586-1593.	5.5	56
67	Abnormal glucose tolerance, white blood cell count, and telomere length in newly diagnosed, antidepressant-naïve patients with depression. <i>Brain, Behavior, and Immunity</i> , 2013, 28, 49-53.	4.1	71
68	A glioblastoma neurosphere line with alternative lengthening of telomeres. <i>Acta Neuropathologica</i> , 2013, 126, 607-608.	7.7	9
69	Prostate Cancer Cell Telomere Length Variability and Stromal Cell Telomere Length as Prognostic Markers for Metastasis and Death. <i>Cancer Discovery</i> , 2013, 3, 1130-1141.	9.4	77
70	Tracking the clonal origin of lethal prostate cancer. <i>Journal of Clinical Investigation</i> , 2013, 123, 4918-4922.	8.2	440
71	Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors. <i>Modern Pathology</i> , 2012, 25, 1033-1039.	5.5	155
72	Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. <i>Oncotarget</i> , 2012, 3, 709-722.	1.8	532

#	ARTICLE	IF	CITATIONS
73	Coordinate regulation between expression levels of telomere-binding proteins and telomere length in breast carcinomas. <i>Cancer Medicine</i> , 2012, 1, 165-175.	2.8	14
74	Telomere Length Is Related to Alternative Splice Patterns of Telomerase in Thyroid Tumors. <i>American Journal of Pathology</i> , 2011, 179, 1415-1424.	3.8	19
75	Prevalence of the Alternative Lengthening of Telomeres Telomere Maintenance Mechanism in Human Cancer Subtypes. <i>American Journal of Pathology</i> , 2011, 179, 1608-1615.	3.8	423
76	The potential utility of telomere-related markers for cancer diagnosis. <i>Journal of Cellular and Molecular Medicine</i> , 2011, 15, 1227-1238.	3.6	43
77	Markers of fibrosis and epithelial to mesenchymal transition demonstrate field cancerization in histologically normal tissue adjacent to breast tumors. <i>International Journal of Cancer</i> , 2011, 129, 1310-1321.	5.1	74
78	Shorter telomeres in luminal B, HER-2 and triple-negative breast cancer subtypes. <i>Modern Pathology</i> , 2011, 24, 194-200.	5.5	25
79	Telomeres are shortened in acinar-to-ductal metaplasia lesions associated with pancreatic intraepithelial neoplasia but not in isolated acinar-to-ductal metaplasias. <i>Modern Pathology</i> , 2011, 24, 256-266.	5.5	34
80	Altered Telomeres in Tumors with <i>ATR</i> and <i>DAXX</i> Mutations. <i>Science</i> , 2011, 333, 425-425.	12.6	891
81	Mutation of a single allele of the cancer susceptibility gene <i>BRCA1</i> leads to genomic instability in human breast epithelial cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 17773-17778.	7.1	134
82	Organ-wide telomeric status in diseased and disease-free prostatic tissues. <i>Prostate</i> , 2010, 70, 1471-1479.	2.3	23
83	Telomere DNA Content in Prostate Biopsies Predicts Early Rise in Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer. <i>Urology</i> , 2010, 75, 724-729.	1.0	20
84	Telomere Length and Pulse Pressure in Newly Diagnosed, Antipsychotic-Naive Patients With Nonaffective Psychosis. <i>Schizophrenia Bulletin</i> , 2009, 35, 437-442.	4.3	92
85	Genomic instability demonstrates similarity between DCIS and invasive carcinomas. <i>Breast Cancer Research and Treatment</i> , 2009, 117, 17-24.	2.5	16
86	Mammary field cancerization: molecular evidence and clinical importance. <i>Breast Cancer Research and Treatment</i> , 2009, 118, 229-239.	2.5	114
87	The alternative lengthening of telomeres phenotype in breast carcinoma is associated with HER-2 overexpression. <i>Modern Pathology</i> , 2009, 22, 1423-1431.	5.5	45
88	Telomere DNA Content Predicts Breast Cancer-Free Survival Interval. <i>Clinical Cancer Research</i> , 2007, 13, 7037-7043.	7.0	37
89	Assessment of the Frequency of Allelic Imbalance in Human Tissue Using a Multiplex Polymerase Chain Reaction System. <i>Journal of Molecular Diagnostics</i> , 2007, 9, 266-271.	2.8	6
90	Diagnostic significance of allelic imbalance in cancer. <i>Expert Opinion on Medical Diagnostics</i> , 2007, 1, 159-168.	1.6	1

#	ARTICLE	IF	CITATIONS
91	A novel loss-of-function mutation in TP53 in an endometrial cancer cell line and uterine papillary serous carcinoma model. <i>Molecular and Cellular Biochemistry</i> , 2007, 297, 179-187.	3.1	12
92	Protease nexin-1 expression is altered in human breast cancer. <i>Cancer Cell International</i> , 2006, 6, 16.	4.1	23
93	Telomere content correlates with stage and prognosis in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2006, 99, 193-202.	2.5	64
94	Telomere DNA content and allelic imbalance demonstrate field cancerization in histologically normal tissue adjacent to breast tumors. <i>International Journal of Cancer</i> , 2006, 119, 108-116.	5.1	72
95	Telomeres: Prognostic markers for solid tumors. <i>International Journal of Cancer</i> , 2006, 119, 2255-2260.	5.1	97
96	ASSOCIATION BETWEEN CANCER-FREE SURVIVAL AND TELOMERE DNA CONTENT IN PROSTATE TUMORS. <i>Journal of Urology</i> , 2005, 173, 610-614.	0.4	73
97	Chemiluminescent Measurement of Telomere DNA Content in Biopsies. <i>BioTechniques</i> , 2002, 33, 144-148.	1.8	23